乳腺癌的分子亚型与局部区域控制
Molecular Subtypes and Local-Regional Control of Breast Cancer.
作者信息
Fragomeni Simona Maria, Sciallis Andrew, Jeruss Jacqueline S
机构信息
Division of Gynecologic Oncology, Multidisciplinary Breast Center, Catholic University of the Sacred Heart of Rome, L.go Agostino Gemelli 8, 00168 Rome, Italy.
Division of Anatomic Pathology, Department of Pathology, University of Michigan, Ann Arbor, MI 48105, USA.
出版信息
Surg Oncol Clin N Am. 2018 Jan;27(1):95-120. doi: 10.1016/j.soc.2017.08.005.
Abstract
In the era of personalized medicine, there has been significant progress regarding the molecular analysis of breast cancer subtypes. Research efforts have focused on how classification of subtypes could provide information on prognosis and influence treatment planning. Although much is known about the impact of different molecular subtypes on disease-specific survival, more recent studies have investigated the role of the different molecular subtypes on local-regional recurrence. This is an area of active study, and in recent years there has been significant progress. This article describes outcomes among disease subtypes to aid in optimal surgical decision-making to improve local-regional control.
摘要
在个性化医疗时代，乳腺癌亚型的分子分析取得了重大进展。研究工作聚焦于亚型分类如何能提供预后信息并影响治疗方案的制定。尽管对于不同分子亚型对疾病特异性生存的影响已有很多了解，但最近的研究探讨了不同分子亚型在局部区域复发中的作用。这是一个活跃的研究领域，近年来已取得显著进展。本文描述了不同疾病亚型的治疗结果，以辅助做出最佳手术决策，从而改善局部区域控制。
相似文献
1
Molecular Subtypes and Local-Regional Control of Breast Cancer.乳腺癌的分子亚型与局部区域控制
Surg Oncol Clin N Am. 2018 Jan;27(1):95-120. doi: 10.1016/j.soc.2017.08.005.
2
Insights into the theranostic value of precision medicine on advanced radiotherapy to breast cancer.精准医学对晚期乳腺癌放射治疗的治疗价值的深入了解。
Int J Med Sci. 2021 Jan 1;18(3):626-638. doi: 10.7150/ijms.49544. eCollection 2021.
3
Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level.基于单细胞水平 lncRNAs 异质性分析的乳腺癌精准治疗探索。
BMC Cancer. 2021 Aug 13;21(1):918. doi: 10.1186/s12885-021-08617-7.
4
Molecular profiling: an essential technology enabling personalized medicine in breast cancer.分子谱分析：使乳腺癌个体化医学成为可能的关键技术。
Curr Drug Targets. 2012 Apr;13(4):541-54. doi: 10.2174/138945012799499767.
5
The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.预后良好的乳腺癌特殊组织学亚型中的21基因复发评分
Breast Cancer Res Treat. 2017 Aug;165(1):65-76. doi: 10.1007/s10549-017-4326-1. Epub 2017 Jun 3.
6
The Role of MicroRNA as Clinical Biomarkers for Breast Cancer Surgery and Treatment.miRNA 作为乳腺癌手术和治疗的临床生物标志物的作用。
Int J Mol Sci. 2021 Aug 1;22(15):8290. doi: 10.3390/ijms22158290.
7
Genetic heterogeneity in breast cancer: the road to personalized medicine?乳腺癌的遗传异质性：通向个体化医学之路？
BMC Med. 2013 Jun 18;11:151. doi: 10.1186/1741-7015-11-151.
8
Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.对 1200 例胰腺导管腺癌的基因表达谱分析揭示了新的亚型。
BMC Cancer. 2018 May 29;18(1):603. doi: 10.1186/s12885-018-4546-8.
9
Advances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized Medicine.乳腺癌分子分析进展：迈向个性化医疗之路
Cancer Control. 2015 Apr;22(2):211-9. doi: 10.1177/107327481502200213.
10
Research-based PAM50 signature and long-term breast cancer survival.基于研究的 PAM50 标志物与长期乳腺癌生存
Breast Cancer Res Treat. 2020 Jan;179(1):197-206. doi: 10.1007/s10549-019-05446-y. Epub 2019 Sep 21.
引用本文的文献
1
Profiling Protein Post-Translational Modifications in Plasma-derived Extracellular Vesicles as Fingerprints for Breast Cancer Subtypes.分析血浆来源的细胞外囊泡中的蛋白质翻译后修饰作为乳腺癌亚型的指纹图谱
Res Sq. 2025 Aug 21:rs.3.rs-7294729. doi: 10.21203/rs.3.rs-7294729/v1.
2
Metabolomic Analysis of Breast Cancer in Colombian Patients: Exploring Molecular Signatures in Different Subtypes and Stages.哥伦比亚乳腺癌患者的代谢组学分析：探索不同亚型和阶段的分子特征
Int J Mol Sci. 2025 Jul 26;26(15):7230. doi: 10.3390/ijms26157230.
3
Comprehensive analysis of glycosyl transferase-related subtypes reveals prognostic genes and immune landscape in breast cancer.糖基转移酶相关亚型的综合分析揭示了乳腺癌的预后基因和免疫格局。
Medicine (Baltimore). 2025 Aug 1;104(31):e43523. doi: 10.1097/MD.0000000000043523.
4
Is Sentinel Lymph Node Biopsy Feasible in Multicentric Breast Cancer? A Case Report and Literature Review.前哨淋巴结活检在多中心性乳腺癌中是否可行？一例病例报告及文献综述。
Life (Basel). 2025 Jun 26;15(7):1018. doi: 10.3390/life15071018.
5
Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy.三阴性乳腺癌中的化学免疫调节：最大化抗PD-1化学免疫治疗疗效的关键
Oncoimmunology. 2025 Dec;14(1):2527303. doi: 10.1080/2162402X.2025.2527303. Epub 2025 Jul 9.
6
Age-related and postmenopausal breast cancer progression and treatment management: The significance of pro-inflammatory cytokines and CXC chemokines.年龄相关性及绝经后乳腺癌的进展与治疗管理：促炎细胞因子和CXC趋化因子的意义
Genes Dis. 2025 Mar 19;12(5):101606. doi: 10.1016/j.gendis.2025.101606. eCollection 2025 Sep.
7
Comparative pharmacological analysis of fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy: Two recently developed chemotherapies in the crucial battle against breast cancer.法米妥珠单抗德鲁替康-nxki与赛托珠单抗戈维汀-hziy的比较药理学分析：两种近期研发的用于抗击乳腺癌关键战役的化疗药物。
Toxicol Rep. 2025 May 21;14:102054. doi: 10.1016/j.toxrep.2025.102054. eCollection 2025 Jun.
8
Assessing the recurrence rate in locally advanced Luminal A patients compared to triple-negative patients in Shahid Rahimi Hospital Khorramabad in 2022: a cross-sectional study.2022年在霍拉马巴德沙希德·拉希米医院评估局部晚期管腔A型患者与三阴性患者的复发率：一项横断面研究。
Ann Med Surg (Lond). 2025 May 13;87(6):3123-3127. doi: 10.1097/MS9.0000000000003338. eCollection 2025 Jun.
9
Molecular Subtypes and Ki-67 index in Breast Carcinoma with Special Emphasis on Triple Negative Breast Cancer. A 3-year Study in a Tertiary Care Center.乳腺癌的分子亚型与Ki-67指数，特别关注三阴性乳腺癌。在一家三级护理中心进行的为期3年的研究。
Indian J Surg Oncol. 2025 Apr;16(2):478-490. doi: 10.1007/s13193-023-01773-1. Epub 2023 May 30.
10
NEDD4 signaling: a new frontier in the diagnosis and treatment of breast and ovarian cancers.NEDD4信号传导：乳腺癌和卵巢癌诊断与治疗的新前沿。
Med Oncol. 2025 May 6;42(6):200. doi: 10.1007/s12032-025-02751-z.
本文引用的文献
1
How could breast cancer molecular features contribute to locoregional treatment decision making?乳腺癌分子特征如何有助于局部区域治疗决策？
Crit Rev Oncol Hematol. 2017 Feb;110:43-48. doi: 10.1016/j.critrevonc.2016.12.006. Epub 2016 Dec 8.
2
Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.除了根据2013年圣加仑会议定义的乳腺癌亚型外，组织学分级还提供了重要的预后信息。
Acta Oncol. 2017 Jan;56(1):68-74. doi: 10.1080/0284186X.2016.1237778. Epub 2016 Oct 20.
3
Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.乳房切除术后放疗：美国临床肿瘤学会、美国放射肿瘤学会和外科肿瘤学会聚焦指南更新
Pract Radiat Oncol. 2016 Nov-Dec;6(6):e219-e234. doi: 10.1016/j.prro.2016.08.009. Epub 2016 Sep 19.
4
Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study.常规临床护理中乳腺癌分子亚型的预后：一项大型前瞻性队列研究。
BMC Cancer. 2016 Sep 15;16(1):734. doi: 10.1186/s12885-016-2766-3.
5
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.70 基因特征作为早期乳腺癌治疗决策的辅助手段。
N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.
6
Luminal B breast cancer: patterns of recurrence and clinical outcome.腔面B型乳腺癌：复发模式与临床结局
Oncotarget. 2016 Oct 4;7(40):65024-65033. doi: 10.18632/oncotarget.11344.
7
Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.前哨淋巴结转移患者行前哨淋巴结清扫术加或不加腋窝清扫术后的局部区域复发：美国外科医师学会肿瘤学组（联盟）ACOSOG Z0011随机试验的长期随访
Ann Surg. 2016 Sep;264(3):413-20. doi: 10.1097/SLA.0000000000001863.
8
Digital image analysis outperforms manual biomarker assessment in breast cancer.数字图像分析在乳腺癌中的表现优于手动生物标志物评估。
Mod Pathol. 2016 Apr;29(4):318-29. doi: 10.1038/modpathol.2016.34. Epub 2016 Feb 26.
9
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.利用生物标志物指导早期浸润性乳腺癌女性辅助性全身治疗决策：美国临床肿瘤学会临床实践指南
J Clin Oncol. 2016 Apr 1;34(10):1134-50. doi: 10.1200/JCO.2015.65.2289. Epub 2016 Feb 8.
10
Identification of Risk Factors for Locoregional Recurrence in Breast Cancer Patients with Nodal Stage N0 and N1: Who Could Benefit from Post-Mastectomy Radiotherapy?腋窝淋巴结分期为N0和N1的乳腺癌患者局部区域复发危险因素的识别：哪些患者能从乳房切除术后放疗中获益？
PLoS One. 2015 Dec 21;10(12):e0145463. doi: 10.1371/journal.pone.0145463. eCollection 2015.
Zotero 插件